Funding for this research was provided by:
Oxford Experimental Cancer Centre
Received: 27 April 2021
Accepted: 6 July 2021
First Online: 23 July 2021
: The study was approved by the Health Research Authority South Central Oxford Research Ethics Committee (REC:10/H0604/85) and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent prior to participation in the trial.
: Not applicable.
: Graham P. Collins has received personal fees from Celleron Therapeutics for work performed as part of the current study. John Whittaker, Nick La Thangue, and David Kerr are directors of Celleron Therapeutics. Celleron Therapeutics was involved in the design of the study. The Oxford Centre for Experimental Cancer Medicine was involved in design of the study, data collection, analysis, and interpretation.